- Home
- DBVT vs CHEB Comparison
DBVT vs CHEB Comparison
Compare DBVT & CHEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBVT
- CHEB
- Stock Information
- Founded
- DBVT 2002
- CHEB 2024
- Country
- DBVT France
- CHEB Singapore
- Employees
- DBVT N/A
- CHEB N/A
- Industry
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- CHEB
- Sector
- DBVT Health Care
- CHEB
- Exchange
- DBVT Nasdaq
- CHEB NYSE
- Market Cap
- DBVT 102.0M
- CHEB 120.0M
- IPO Year
- DBVT N/A
- CHEB 2024
- Fundamental
- Price
- DBVT $6.46
- CHEB $10.29
- Analyst Decision
- DBVT Strong Buy
- CHEB
- Analyst Count
- DBVT 2
- CHEB 0
- Target Price
- DBVT $22.50
- CHEB N/A
- AVG Volume (30 Days)
- DBVT 1.1M
- CHEB 80.9K
- Earning Date
- DBVT 05-06-2025
- CHEB 01-01-0001
- Dividend Yield
- DBVT N/A
- CHEB N/A
- EPS Growth
- DBVT N/A
- CHEB N/A
- EPS
- DBVT N/A
- CHEB N/A
- Revenue
- DBVT $4,200,000.00
- CHEB N/A
- Revenue This Year
- DBVT $1,679.52
- CHEB N/A
- Revenue Next Year
- DBVT $535.67
- CHEB N/A
- P/E Ratio
- DBVT N/A
- CHEB N/A
- Revenue Growth
- DBVT N/A
- CHEB N/A
- 52 Week Low
- DBVT $0.44
- CHEB $9.96
- 52 Week High
- DBVT $7.28
- CHEB $26.25
- Technical
- Relative Strength Index (RSI)
- DBVT 65.77
- CHEB N/A
- Support Level
- DBVT $3.91
- CHEB N/A
- Resistance Level
- DBVT $7.28
- CHEB N/A
- Average True Range (ATR)
- DBVT 0.60
- CHEB 0.00
- MACD
- DBVT 0.20
- CHEB 0.00
- Stochastic Oscillator
- DBVT 75.67
- CHEB 0.00
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
About CHEB CHENGHE ACQUISITION II CO
Chenghe Acquisition II Co is a blank check company.